Results 81 to 90 of about 1,652 (181)

Supplementary Figures and Tables from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

, 2023
<p>Supplementary Figures and Tables</p>
Patricia M. LoRusso, Michael E. Berens, Lance K. Heilbrun, Harshil D. Dhruv, Shwetal Mehta, Alanna Derogatis, Seongho Kim, Jianmei Wu, Karri Stark, Julie Boerner, Jing Li, Nader Sanai   +11 more
openaire   +1 more source

Cell cycle machinery in oncology: A comprehensive review of therapeutic targets

The FASEB Journal, Volume 38, Issue 11, 15 June 2024.
The cell cycle machinery and checkpoints. ATM, ataxia telangiectasia‐mutated protein kinase; ATR, ATM and Rad3‐related protein kinase; Bub3, budding uninhibited by benzimidazoles‐3 protein; BubR1, Bub1‐related protein‐1; CDC25C, cell division cycle 25C; CDK, cyclin‐dependent kinase; CHK1, checkpoint kinase 1; E2F, E2 transcription factor; Mad2, mitotic
Simona Cavalu, Amir Mohamed Abdelhamid, Sameh Saber, Elsayed A. Elmorsy, Rabab S. Hamad, Mustafa Ahmed Abdel‐Reheim, Galal Yahya, Mohamed M. Salama   +7 more
wiley   +1 more source

Supplementary Video S1 from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation

, 2017
Live cell imaging of histone-H2B-RFP expressing PCI13-G245D cells in the presence of AZD1775.
Faye Johnson (11483644), Abdullah A. Osman (14920271), Curtis R. Pickering (13115535), Jeffrey N. Myers (222748), Noriaki Tanaka (8478), Nene N. Kalu (14933612), Tseng-Cheng Chen (558642), Mitchell J. Frederick (14871290), Antje Lindemann (15008477), Walter N. Hittelman (1274439), Siqing Fu (160695), Marek Kimmel (39636), Frederico O. Gleber-Netto (13907530), Ameeta A. Patel (14921678), Hideaki Takahashi (1269621), Jing Wang (6206297), Xiayu Rao (790781), Natalie L. Silver (14997050), Roman Jaksik (6309656), Jiping Wang (1319202), Lin Tang (65412)   +20 more
core   +1 more source

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

Cancer Communications, Volume 44, Issue 3, Page 297-360, March 2024.
Abstract Cancer is a leading cause of death worldwide. Targeted therapies aimed at key oncogenic driver mutations in combination with chemotherapy and radiotherapy as well as immunotherapy have benefited cancer patients considerably. Tumor protein p53 (TP53), a crucial tumor suppressor gene encoding p53, regulates numerous downstream genes and cellular
Bin Song, Ping Yang, Shuyu Zhang
wiley   +1 more source

Preclinical assessment of Wee1 inhibitor AZD1775 and DNA damaging agents in the chemotherapeutic treatment of esophageal adenocarcinoma with mutated TP53

, 2016
: Background: Esophageal adenocarcinoma (EAC) is one of the only malignancies whose incidence is rising in the United States. Current multidrug treatment for EAC has considerable toxic side effects that necessitate the development of less toxic, more ...

core  

Identifying and overcoming mechanisms of resistance to Wee1 kinase inhibitor (AZD1775) in high grade serous ovarian cancer [PDF]

, 2019
High grade serous ovarian cancer (HGSOC) comprises 75-80% of all ovarian cancer cases and is characterised by p53 mutation and genetic heterogeneity. There are two major molecular categories: homologous recombination repair (HR) pathway proficient and ...
Gomez, Miriam Kathleen
core  

Supplementary Figures 1-3 from Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer

, 2014
Supplementary Figure 1. The effects of AZD1775 and olaparib on the radiation-induced G2 checkpoint; S2: Sub-G1 DNA content following AZD1775, olaparib, and radiation treatments; S3: Weight loss associated with combined treatment with AZD1775, olaparib ...
Jordan R. Robertson (14987205), Katherine B. Marsh (15001190), Jonathan Maybaum (1910515), David Karnak (14986820), Leslie A. Parsels (9291352), Theodore S. Lawrence (9291361), Meredith A. Morgan (9291364), Lili Zhao (442802), Dongping Wei (14905512), Mary A. Davis (6577793), Carl G. Engelke (14932242), Tasneem Kausar (2917892)   +11 more
core   +1 more source

DataSheet_1_Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo.pdf

, 2019
Esophageal squamous cell carcinoma (ESCC) is a common malignant diagnosed cancer with increasing incidence rate and few treatment options. As a specific small-molecule inhibitor of the Wee1 tyrosine kinase, AZD1775 has previously shown potent antitumor ...
Zhijun Zhao (784822), Songqiang Xie (1750744), Qiuren Wei (7119242), Chaojie Wang (2175530), Liang Chen (73736), Shuning Bi (5775887)   +5 more
core   +1 more source

Supplementary Table S3 from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation

, 2017
Major pathways significantly associated with the top filtered differentially expressed genes regulated by vorinostat or in combination with AZD1775 identified by the GO enrichment and IP analyses.
Faye Johnson (11483644), Abdullah A. Osman (14920271), Curtis R. Pickering (13115535), Jeffrey N. Myers (222748), Noriaki Tanaka (8478), Nene N. Kalu (14933612), Tseng-Cheng Chen (558642), Mitchell J. Frederick (14871290), Antje Lindemann (15008477), Walter N. Hittelman (1274439), Siqing Fu (160695), Marek Kimmel (39636), Frederico O. Gleber-Netto (13907530), Ameeta A. Patel (14921678), Hideaki Takahashi (1269621), Jing Wang (6206297), Xiayu Rao (790781), Natalie L. Silver (14997050), Roman Jaksik (6309656), Jiping Wang (1319202), Lin Tang (65412)   +20 more
core   +1 more source

Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis

, 2018
Based on the mechanisms by which Wee1 inhibitor and cisplatin played their own role, a promising strategy of Wee1 inhibitor combined with cisplatin was proposed, which was investigated in gastric cancer (GC).
Dongshao Chen, Zhongwu Li, Xiaotian Zhang, Cheng Zhang, Jing Gao, Bin Dong, Xiaoting Lin, Lin Shen   +7 more
core   +1 more source